Skip to main content
Top
Published in: Supportive Care in Cancer 4/2014

01-04-2014 | Original Article

Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors

Authors: G. J. van Londen, E. B. Beckjord, M. A. Dew, K. L. Cooper, N. E. Davidson, D. H. Bovbjerg, H. S. Donovan, R. C. Thurston, J. Q. Morse, S. Nutt, R. Rechis

Published in: Supportive Care in Cancer | Issue 4/2014

Login to get access

Abstract

Background

Breast cancer survivors often receive long-term adjuvant endocrine therapy (AET) to reduce recurrence risk. Adherence to AET is suboptimal, which may be due to the experience of symptoms and/or concerns. Few studies have comprehensively assessed self-reported concerns between those who currently, previously or have never received AET. The study objective is to describe self-reported physical and emotional concerns of breast cancer survivors who are current, prior, or never-recipients of AET.

Methods

Secondary analysis was performed on a subset of survey data collected in the 2010 LIVESTRONG Survey. Breast cancer survivors (n = 1,013, mean 5.4 years post-diagnosis) reported on 14 physical and eight emotional concerns that began after diagnosis and were experienced within 6 months of participation in the survey. Bivariate analyses examined the prevalence of each concern by AET status. The relationships between AET and burden of physical or emotional concerns were modeled with logistic regression.

Results

More than 50 % of the participants reported currently experiencing cognitive issues, fatigue, fear of recurrence, emotional distress, and identity/grief issues. Thyroid dysfunction and stigma concerns were more common among participants with prior AET (p < 0.01), while fear of recurrence, emotional distress, and concern about appearance were more common among those currently receiving AET (p < 0.01). Fatigue, sexual dysfunction, and pain were more common among prior and current AET recipients (p < 0.01). In adjusted models, receipt of AET was associated with a higher number of physical, but not emotional concerns. A higher number of concerns was associated with younger age, having children, receipt of chemotherapy, longer duration of cancer treatment, and shorter time since diagnosis (p < 0.01).

Conclusions

Breast cancer survivors who received AET were at risk of developing a variety of physical and emotional concerns, many of which persisted after treatment. These findings suggest the importance of developing individualized, supportive resources for breast cancer survivors.
Literature
2.
go back to reference Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28PubMedCentralPubMedCrossRef Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9(3):R28PubMedCentralPubMedCrossRef
3.
go back to reference Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796. doi:10.1200/JCO.2009.26.3756 PubMedCrossRef Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796. doi:10.​1200/​JCO.​2009.​26.​3756 PubMedCrossRef
6.
go back to reference Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942. doi:10.1200/JCO.2011.38.0261 PubMedCentralPubMedCrossRef Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942. doi:10.​1200/​JCO.​2011.​38.​0261 PubMedCentralPubMedCrossRef
7.
9.
go back to reference Bloom JR, Kang SH, Petersen DM, Stewart SL (2007) Quality of life in long-term cancer survivors. In: Feuerstein M (ed) Handbook of cancer survivorship. Springer Science + Business Media, New York, pp 43–65CrossRef Bloom JR, Kang SH, Petersen DM, Stewart SL (2007) Quality of life in long-term cancer survivors. In: Feuerstein M (ed) Handbook of cancer survivorship. Springer Science + Business Media, New York, pp 43–65CrossRef
10.
go back to reference Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, Rowden D (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118(8 Suppl):2207–2216. doi:10.1002/cncr.27469 PubMedCrossRef Binkley JM, Harris SR, Levangie PK, Pearl M, Guglielmino J, Kraus V, Rowden D (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118(8 Suppl):2207–2216. doi:10.​1002/​cncr.​27469 PubMedCrossRef
12.
go back to reference Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2010) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-1132-4 Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2010) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-1132-4
13.
14.
15.
go back to reference Murgic J, Soldic Z, Vrljic D, Samija I, Kirac I, Bolanca A, Kusic Z (2012) Quality of life of Croatian breast cancer patients receiving adjuvant treatment—comparison to long-term breast cancer survivors. Coll Anthropol 36(4):1335–1341 Murgic J, Soldic Z, Vrljic D, Samija I, Kirac I, Bolanca A, Kusic Z (2012) Quality of life of Croatian breast cancer patients receiving adjuvant treatment—comparison to long-term breast cancer survivors. Coll Anthropol 36(4):1335–1341
16.
go back to reference Rechis R, Reynolds KA, Beckjord EB, Nutt S, Burns RM, Schaefer JS (2011) "I Learned to Live With It" is not good enough: challenges reported by post-treatment cancer survivors in the LIVESTRONG Surveys. LIVESTRONG, Austin Rechis R, Reynolds KA, Beckjord EB, Nutt S, Burns RM, Schaefer JS (2011) "I Learned to Live With It" is not good enough: challenges reported by post-treatment cancer survivors in the LIVESTRONG Surveys. LIVESTRONG, Austin
17.
go back to reference Aziz NM (2007) Late effects of cancer treatments. In Ganz PA (ed) Cancer survivorship: today and tomorrow. Springer Science, New York, pp 54–76 Aziz NM (2007) Late effects of cancer treatments. In Ganz PA (ed) Cancer survivorship: today and tomorrow. Springer Science, New York, pp 54–76
18.
go back to reference Casillas J, Ganz P (2009) Physical late effects of cancer: Implications for care. In: Miller SM, Bowen DJ, Croyle RT, Rowland JH (eds) Handbook of cancer control and behavioral science: a resource for researchers, practitioners, and policymakers. American Psychological Association, Washington, DC, pp 431–448 Casillas J, Ganz P (2009) Physical late effects of cancer: Implications for care. In: Miller SM, Bowen DJ, Croyle RT, Rowland JH (eds) Handbook of cancer control and behavioral science: a resource for researchers, practitioners, and policymakers. American Psychological Association, Washington, DC, pp 431–448
19.
go back to reference Demark-Wahnefried W, Aziz NM (2009) Health promotion and disease prevention in adult cancer survivors. In: Miller SM, Bowen DJ, Croyle RT, Rowland JH (eds) Handbook of cancer control and behavioral science: a resource for researchers, practitioners, and policymakers. American Psychological Association, Washington, DC, pp 487–494 Demark-Wahnefried W, Aziz NM (2009) Health promotion and disease prevention in adult cancer survivors. In: Miller SM, Bowen DJ, Croyle RT, Rowland JH (eds) Handbook of cancer control and behavioral science: a resource for researchers, practitioners, and policymakers. American Psychological Association, Washington, DC, pp 487–494
21.
go back to reference Stricker CT, Jacobs LA (2008) Physical late effects in adult cancer survivors. Oncology (Williston Park) 22(8 Suppl Nurse Ed):33–41 Stricker CT, Jacobs LA (2008) Physical late effects in adult cancer survivors. Oncology (Williston Park) 22(8 Suppl Nurse Ed):33–41
22.
go back to reference Avis NE, Smith KW, McGraw S, Smith RG, Petronis VM, Carver CS (2005) Assessing quality of life in adult cancer survivors (QLACS). Qual Life Res 14(4):1007–1023PubMedCrossRef Avis NE, Smith KW, McGraw S, Smith RG, Petronis VM, Carver CS (2005) Assessing quality of life in adult cancer survivors (QLACS). Qual Life Res 14(4):1007–1023PubMedCrossRef
23.
go back to reference Alfano CM, Rowland JH (2006) Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J 12(5):432–443PubMedCrossRef Alfano CM, Rowland JH (2006) Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J 12(5):432–443PubMedCrossRef
25.
go back to reference Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F, Cecchetti D, Martino E, Pinchera A (1996) Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 81(3):990–994PubMed Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F, Cecchetti D, Martino E, Pinchera A (1996) Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 81(3):990–994PubMed
27.
go back to reference Fan HG, Houede-Tchen N, Yi QL, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23(31):8025–8032. doi:10.1200/JCO.2005.01.6550 PubMedCrossRef Fan HG, Houede-Tchen N, Yi QL, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23(31):8025–8032. doi:10.​1200/​JCO.​2005.​01.​6550 PubMedCrossRef
28.
go back to reference Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23(4):882–890. doi:10.1093/annonc/mdr330 PubMedCrossRef Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, Carrieri MP, Giorgi R (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 23(4):882–890. doi:10.​1093/​annonc/​mdr330 PubMedCrossRef
Metadata
Title
Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors
Authors
G. J. van Londen
E. B. Beckjord
M. A. Dew
K. L. Cooper
N. E. Davidson
D. H. Bovbjerg
H. S. Donovan
R. C. Thurston
J. Q. Morse
S. Nutt
R. Rechis
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-2041-y

Other articles of this Issue 4/2014

Supportive Care in Cancer 4/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine